Agenus Inc. (NASDAQ:AGEN)
Agenus Inc. (NASDAQ:AGEN) represented a move of 4.78 percent or $-0.13 per share and closed its previous day trading session at $2.41. 939125 Shares were traded in the last trading session with an Average Volume of 1.14 Million Shares. The stock currently has a Market Capitalization of 275.99 Million.
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
The stock traded between $1.54 and $6.19 over 1-Year time period showing its price to sales ratio of 7.13. Agenus Inc. (NASDAQ:AGEN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $19.57 and 200-Day Simple Moving Average of $-18.47. Its Price to Free Cash Flow is 0 and Price to Book of 0.
Analyst’s recommended the stock as 1 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Agenus Inc. (NASDAQ:AGEN) reported its Actual EPS of $-0.29/share. The analysts offering Earnings Estimates for the company were believing that Agenus Inc. could bring EPS of $-0.25/share. The difference between Actual EPS and Estimated EPS was -0.04 Percent. Thus showing an Earnings Surprise of -16 Percent.
BioScrip, Inc. (NASDAQ:BIOS)
In the last trading session, BioScrip, Inc. (NASDAQ:BIOS) added its value by 1.28% closing at the price of $3.95. The stock currently has market capitalization of 503.74 Million, with average volume of 598.72 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently BioScrip, Inc. (NASDAQ:BIOS) is showing beta of 0.47. This particular value of beta suggests that BioScrip, Inc. (NASDAQ:BIOS) has historically moved 47% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for BioScrip, Inc. (NASDAQ:BIOS) is at $-0.93.
The stock currently has RSI of 78.03. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.
BioScrip, Inc. (NASDAQ:BIOS) topped its 52-week high price of $4.13 on 11/29/18 and 52-Week Low Price of $2.31 on 04/02/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.61% and monthly volatility of 5.60% respectively.